精神分裂症长期抗精神病药治疗的获益-风险比
该文批判性综述了精神分裂症长期持续抗精神病药治疗的疗效、有效性及不良反应证据。短期和中期疗效证据一致,长期疗效证据不足;基于国家登记的研究显示持续治疗在有效性上占优且与较低死亡率相关,但慢性使用与代谢紊乱和迟发性运动障碍相关。总体证据支持获益-风险比有利,但不支持对稳定期患者安全大幅减量。
要点
- 短期和中期证据一致支持抗精神病药在急性精神病性症状稳定后的疗效,长期疗效证据不足。
- 基于国家登记的低偏倚长期研究显示持续抗精神病药治疗在有效性上占优,且与较低死亡率相关。
- 慢性抗精神病药使用与代谢紊乱和迟发性运动障碍相关,但总体获益-风险比有利。
核心结论
- 总体证据表明,尽管长期使用抗精神病药可能带来神经和代谢方面不良反应,但支持其长期疗效和有效性(包括对预期寿命影响)的证据超过反对证据,总体获益-风险比有利。
研究设计与样本
- 本文为批判性文献综述,检索并评估关于精神分裂症长期持续抗精神病药治疗的疗效、有效性、不良反应、躯体疾病与死亡率影响及神经生物学相关性的文献。
主要发现
- 短期和中期证据一致支持抗精神病药在急性精神病性症状稳定后的疗效,但支持该效应在长期发生改变的证据不足。
- 多数但非全部长期队列研究发现慢性抗精神病药治疗期间疗效下降,但因偏倚风险高(包括不依从增加)而结论不确定。
- 基于国家登记的低偏倚长期研究显示持续抗精神病药治疗在有效性上占优。
- 持续抗精神病药治疗与精神分裂症患者较低死亡率一致相关。
- 慢性抗精神病药使用与代谢紊乱和迟发性运动障碍相关,后者是脑功能受潜在影响的明确不良临床后果,可能源于多巴胺能超敏,但无其他不可逆神经生物学改变的明确证据。
关键数值与推荐
- 当前文献不支持对接受辅助心理社会干预的稳定期个体将抗精神病药剂量安全降低50%或更多。
临床怎么用
- 临床应重视持续抗精神病药治疗对有效性和死亡率的有利影响,同时监测代谢紊乱和迟发性运动障碍等不良反应。
- 辅助心理社会干预被认为对实现康复至关重要,但不应据此对稳定期患者大幅降低抗精神病药剂量。
- 对初始精神病性表现后长期未复发的一小部分患者,需进一步研究阳性结局的患者层面预测因素。
局限性
- 长期队列研究存在广泛偏倚风险,包括不依从增加,导致结果不确定。
- 支持抗精神病药长期疗效的证据不足,长期效应是否改变尚不明确。
- 需要进一步研究以识别初始精神病性表现后长期无复发患者的预测因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The long-term benefit-to-risk ratio of sustained antipsychotic treatment for schizophrenia has recently been questioned. In this paper, we critically examine the literature on the long-term efficacy and effectiveness of this treatment. We also review the evidence on the undesired effects, the impact on physical morbidity and mortality, as well as the neurobiological correlates of chronic exposure to antipsychotics. Finally, we summarize factors that affect the risk-benefit ratio. There is consistent evidence supporting the efficacy of antipsychotics in the short term and mid term following stabilization of acute psychotic symptoms. There is insufficient evidence supporting the notion that this effect changes in the long term. Most, but not all, of the long-term cohort studies find a decrease in efficacy during chronic treatment with antipsychotics. However, these results are inconclusive, given the extensive risk of bias, including increasing non-adherence. On the other hand, long-term studies based on national registries, which have lower risk of bias, find an advantage in terms of effectiveness during sustained antipsychotic treatment. Sustained antipsychotic treatment has been also consistently associated with lower mortality in people with schizophrenia compared to no antipsychotic treatment. Nevertheless, chronic antipsychotic use is associated with metabolic disturbance and tardive dyskinesia. The latter is the clearest undesired clinical consequence of brain functioning as a potential result of chronic antipsychotic exposure, likely from dopaminergic hypersensitivity, without otherwise clear evidence of other irreversible neurobiological changes. Adjunctive psychosocial interventions seem critical for achieving recovery. However, overall, the current literature does not support the safe reduction of antipsychotic dosages by 50% or more in stabilized individuals receiving adjunctive psychosocial interventions. In conclusion, the critical appraisal of the literature indicates that, although chronic antipsychotic use can be associated with undesirable neurologic and metabolic side effects, the evidence supporting its long-term efficacy and effectiveness, including impact on life expectancy, outweighs the evidence against this practice, overall indicating a favorable benefit-to-risk ratio. However, the finding that a minority of individuals diagnosed initially with schizophrenia appear to be relapse free for long periods, despite absence of sustained antipsychotic treatment, calls for further research on patient-level predictors of positive outcomes in people with an initial psychotic presentation.
引用
- Correll CU, Rubio JM, Kane JM, et al. What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia? World Psychiatry. 2018. PMID: 29856543. doi:10.1002/wps.20516
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。